颅内动脉瘤是严重危害人类健康的主要疾病之一。颅内动脉瘤支架置入术作为一种有效的治疗动脉瘤手段，也存在着造成严重并发症(如支架内血栓形成)的风险。项目组前期临床研究发现，氯吡格雷作为术后常规的抗血小板药物，能有效抑制支架内血栓的形成。但是在部分患者中，其非但不能起效，反而使得患者术后并发症加重。近年来国外一些研究表明，CYP2C19等位基因可能与氯吡格雷疗效有关。本项目拟通过前瞻性队列研究，比较支架置入术后服用氯吡格雷后抗血小板效果的个体化差异，探讨CYP2C19基因多态性在颅内动脉瘤支架置入术后对氯吡格雷药效影响，最终为氯吡格雷在支架置入术的个体化选择与治疗提供药物基因组学依据。

Intracranial aneurysm is widely known to create significant health implications. The common use of intracranial stents for the treatment of aneurysms have the potential to cause serious complications such as thrombus formation and secondary lesions. Numerous published studies have clearly proven that the anti-platelet,Clopidogrel, plays an important role in the inhibition of thrombus formation.However, there is a subset of patients who may not display adequate response to the medication leading to more serious complications.CYP2C19 genetic polymorphism is understood to be prevalent in certain subsets of patients. This prospective cohort study intends to compare the individual difference in the efficacy of anti-platelet therapy and investigate the incidence of genetic polymorphism of clopidogrel after stent implantation. The ultimate aim is to establish a pharmacogenomics evidence for individual treatment of clopidogrel in stent implantation of intracranial aneurysm.